Contract Option Exercises — December 23, 2025

Fluor subsidiary holds $25B Savannah River contract (36% of batch value) with $9.1B outlayed; Hanford adds $1.1B tank waste ops.

Boeing ISS ($22B, 24% batch), SpaceX Commercial Crew ($3B, 84% outlayed to 2030), Lockheed ($141M to 2027) affirm long-term R&D funding.

Booz Allen ($353M obligated, $2.6B ceiling), CACI ($399M to $1.3B), Peraton ($277M to $883M) via GSA show multi-year option-rich awards.

McKesson CDC vaccine contract ($153M obligated, $8.1B options to 2029) positions for explosive growth if exercised.

Nonprofit DOE lab ops (Argonne $16.7B, Stanford $14.5B) provide steady but fee-limited revenue to 2026-2027.

Low outlays in 40% of contracts (e.g., Boeing $2.4B vs $22B obligated, BL Harbert $0 vs $730M) signal funding pacing delays.

20+ contracts end 2025-2027 (e.g., Syncom June 2025, KBR Jan 2026) with recompetition risk post-full & open awards.

High subawards (avg 20% value, up to $673M in Aerodyne) across 70% of records introduce subcontractor dependencies.

Cost-plus award fee (60% of batch) ties 10-20% margins to DOE/NASA/CMS evaluations.

$20B+ unexercised options (e.g., McKesson $8B, Booz Allen $2.2B, CACI $946M) offer 20-50x obligation upside if exercised.

Long-tail contracts to 2028-2030 (SpaceX, Noridian, McKesson) amid nuclear/space/health priorities.

High outlay realization (77% avg where reported, e.g., KBR 77%, SpaceX 83%) de-risks revenue recognition.

$26B DOE contracts (28% batch) via cost-plus M&O awards to Fluor/Hanford through 2026.

$27B NASA (30% batch) skewed to incumbents like Boeing/SpaceX/Lockheed despite 2025-2027 ends.

$3B+ GSA awards (Booz, CACI, Peraton, GD) with $5B+ ceilings signal defense/digital modernization spend.

$1.2B CMS/CDC/NIH contracts emphasize IT/hosting (Companion) and vaccines (McKesson).

{"entity"=>"Fluor Corporation", "reason"=>"$25B Savannah River (36% batch value) with $11.7B options; nuclear policy tailwind.", "trigger"=>"Option exercise notice or 2026 recompete RFP"}

{"entity"=>"Boeing Company", "reason"=>"$22B ISS contract (24% batch) low outlay signals pacing risk amid commercial pressures.", "trigger"=>"Outlay acceleration >$500M/quarter or NASA extension"}

{"entity"=>"McKesson Corporation", "reason"=>"$153M obligated but $8B options in CDC vaccines to 2029; highest upside potential.", "trigger"=>"Initial option exercise >$1B"}

{"entity"=>"Jacobs Engineering (Syncom)", "reason"=>"Dual $1.2B NASA Stennis contracts end June 2025; recompete vulnerability.", "trigger"=>"New task order award or extension filing"}